Cerevel Therapeutics Holdings, Inc. - FORM S-1/A - EX-23.1 - EXHIBIT 23.1 - May 29, 2020

Attached files

file filename
S-1/A - S-1/A - Cerevel Therapeutics Holdings, Inc.nt10009663x4_s1a.htm
EX-99.3 - EXHIBIT 99.3 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex99-3.htm
EX-10.8 - EXHIBIT 10.8 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex10-8.htm
EX-10.7 - EXHIBIT 10.7 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex10-7.htm
EX-10.6 - EXHIBIT 10.6 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex10-6.htm
EX-10.5 - EXHIBIT 10.5 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex10-5.htm
EX-10.4 - EXHIBIT 10.4 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex10-4.htm
EX-10.3 - EXHIBIT 10.3 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex10-3.htm
EX-10.2 - EXHIBIT 10.2 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex10-1.htm
EX-5.2 - EXHIBIT 5.2 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex5-2.htm
EX-5.1 - EXHIBIT 5.1 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex5-1.htm
EX-4.4 - EXHIBIT 4.4 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex4-4.htm
EX-4.3 - EXHIBIT 4.3 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex4-3.htm
EX-4.2 - EXHIBIT 4.2 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex4-2.htm
EX-4.1 - EXHIBIT 4.1 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex4-1.htm
EX-3.2 - EXHIBIT 3.2 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex3-2.htm
EX-3.1 - EXHIBIT 3.1 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex3-1.htm
EX-1.1 - EXHIBIT 1.1 - Cerevel Therapeutics Holdings, Inc.nt10009663x4_ex1-1.htm
Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the use in this Registration Statement on Amendment No. 1 to Form S-1, of our report dated April 16, 2020, relating to the balance sheet of ARYA Sciences Acquisition Corp. II as of March 2, 2020, and the related statements of operations, changes in shareholder’s equity and cash flows for the period from February 20, 2020 (inception) through March 2, 2020 and to the reference to our Firm under the caption “Experts” in the Prospectus.

/s/ WithumSmith+Brown, PC
  
   
New York, New York
  
May 28, 2020
  


Cerevel Therapeutics Holdings, Inc. Reports